

Sub E2 Cont

or cellular abnormalities having a tissue type selected from the group consisting of skin, conjunctiva, parietal pleura, visceral pleura, dura mater, meninges, the lining of the group consisting of the mouth, pharynx, esophagus, stomach, intestines, intestinal appendages, rectum, anal canal, nasal passages, nasal sinuses, nasopharynx, trachea, bronchi, and bronchioles, ureters, urinary bladder, urethra, vagina, uterine cervix, uterus, peritoneal cavity, pelvic cavity, surface of the organs contained within the peritoneal cavity, and surface of the organs contained within the pelvic cavity.

RECEIVED
SEP 19 2000
TECH CENTER 1600/2300

- Sub E2 Cont
19. (Amended) A method of treatment, comprising administering to a patient, who is suffering from a disorder caused by an agent of exogenous origin, a therapeutically effective amount of a precursor of protoporphyrin IX, and thereafter exposing said patient to light capable of photoactivating protoporphyrin IX, wherein said disorder is characterized by the presence of lesions or cellular abnormalities having a tissue type selected from the group consisting of skin, conjunctiva, parietal pleura, visceral pleura, dura mater, meninges, the lining of the group consisting of the mouth, pharynx, esophagus, stomach, intestines, intestinal appendages, rectum, anal canal, nasal passages, nasal sinuses, nasopharynx, trachea, bronchi, and bronchioles, ureters, urinary bladder, urethra, vagina, uterine cervix, uterus, peritoneal cavity, pelvic cavity, surface of the organs contained within the peritoneal cavity, and surface of the organs contained within the pelvic cavity.

Please add the following new claims:

- Sub E2 Cont
- 30. A method according to claim 18, wherein said fungus is a member of the genus *Tinea*.
31. A method according to claim 30, wherein said disorder is onychomycosis.
32. A method according to claim 31, wherein said precursor is 5-aminolevulinic acid.
33. A method according to claim 27, wherein said fungus is a member of the genus *Tinea*.
34. A method according to claim 33, wherein said disorder is onychomycosis.
35. A method according to claim 34, wherein said precursor is 5-aminolevulinic acid.
36. A method of treatment comprising administering to a patient, who is suffering from a disorder associated with a fungus, a therapeutically effective amount of a

precursor of protoporphyrin IX, and thereafter exposing the fungus to light capable of photoactivating protoporphyrin IX.

37. A method according to claim 36, wherein said disorder is characterized by the presence of lesions or cellular abnormalities.

38. A method according to claim 37, wherein said lesions or cellular abnormalities are of epithelial or endothelial origin.

39. A method according to claim 38, wherein said lesions or cellular abnormalities are of a tissue origin selected from the group consisting of the skin, circulatory system, conjunctiva, parietal pleura, visceral pleura, dura mater, meninges, tissues containing abnormal cells, suspensions of body fluids containing abnormal cells, and blood.

40. A method according to claim 39, wherein said lesions or cellular abnormalities are found in the tissue lining of an anatomical site from the group consisting of the mouth, pharynx, esophagus, stomach, intestines, intestinal appendages, rectum, anal canal, nasal passages, nasal sinuses, nasopharynx, trachea, bronchi, and bronchioles, ureters, urinary bladder, urethra, vagina, uterine cervix, uterus, peritoneal cavity, pelvic cavity, surface of the organs contained within the peritoneal cavity, and surface of the organs contained within the pelvic cavity

41. A method according to claim 40, wherein said fungus is a member of the genus *Tinea*.

42. A method according to claim 41, wherein said disorder is onychomycosis.

43. A method according to claim 42, wherein said precursor is 5-aminolevulinic acid.

44. A method of treatment comprising administering to a patient, who is suffering from a disorder caused by a fungus, a therapeutically effective amount of a precursor of protoporphyrin IX, and thereafter exposing the fungus to light capable of photoactivating protoporphyrin IX.

45. A method according to claim 44, wherein said disorder is characterized by the presence of lesions or cellular abnormalities.

46. A method according to claim 45, wherein said lesions or cellular abnormalities are of epithelial or endothelial origin.

- Sub
E2
Cont
47. A method according to claim 46, wherein said lesions or cellular abnormalities are of a tissue origin selected from the group consisting of the skin, circulatory system, conjunctiva, parietal pleura, visceral pleura, dura mater, meninges, tissues containing abnormal cells, suspensions of body fluids containing abnormal cells, and blood.
48. A method according to claim 47, wherein said lesions or cellular abnormalities are found in the tissue lining of an anatomical site from the group consisting of the mouth, pharynx, esophagus, stomach, intestines, intestinal appendages, rectum, anal canal, nasal passages, nasal sinuses, nasopharynx, trachea, bronchi, and bronchioles, ureters, urinary bladder, urethra, vagina, uterine cervix, uterus, peritoneal cavity, pelvic cavity, surface of the organs contained within the peritoneal cavity, and surface of the organs contained within the pelvic cavity
49. A method according to claim 45, wherein said fungus is a member of the genus *Tinea*.
50. A method according to claim 49, wherein said disorder is onychomycosis.
51. A method according to claim 50, wherein said precursor is 5-aminolevulinic acid.--
- Sub
E2
Cont

Remarks

Entry of the foregoing claims prior to reexamination is requested. The proposed claims are proper for entry because they do not introduce unsupported subject matter into the claims. The bulk of the new recitations are supported by the original claims. The recitations "Tinea" and "onychomycosis" are supported in the specification *inter alia* at page 37, line 8. Upon entry, claims 1, 15-19, and 24-51 will be pending.

The PTO first rejects claim 1 under the second paragraph of Section 112 as indefinite based on the recitation "agent or cell." It is said that "[t]here is insufficient basis for this limitation earlier in the claim. For the purposes of this examination, claim 1 is being treated as a method of treating a patient." Applicants believe the claim is clear. Nonetheless, the phrase "or cell" has been deleted for clarity.

The PTO next states that the subject claims are only entitled to a priority date of June 5, 1995. Applicants submit that such a finding is unsupportable for at least some of their claims, but for the limited purpose of responding to the present Office Action, it is not